Live Attenuated RSV Vaccines Based on Codon-Pair Deoptimization


The technology includes patent rights and related materials for live attenuated viruses that can be used as a prophylactic vaccine against respiratory syncytial virus. The viruses are generated using codon-pair deoptimization techniques, resulting in attenuation based on hundreds or thousands of nucleotide substitutions with no differences at the amino acid level. Various permutations are based on deoptimization of the RSV polymerase ORF, the F and G glycoprotein ORFs, the NS1, NS2, N, P, M, and SH ORFs, or all of these in combination. Experimental growth data for representative viruses in mice and in African Green Monkeys demonstrated in vivo growth attenuation.

Potential Commercial Applications: Competitive Advantages:
  • Prophylactic vaccine
  • Childhood vaccine
 
  • Live attenuated
  • Codon deoptimized


Development Stage:
  • Pre-clinical
  • In vivo data available (animal)


Inventors:

Peter Collins (NIAID)  ➽ more inventions...

Cyril Le Nouen (NIAID)  ➽ more inventions...

Linda Brock (NIAID)  ➽ more inventions...

Ursula Buchholz (NIAID)  ➽ more inventions...

Joshua DiNapoli (NIAID)  ➽ more inventions...

Eckard Wimmer


Intellectual Property:
U.S. Pat: 9,957,486 issued 2018-05-01
US Application No. 61/762,768
US Application No. 61/794,155
PCT Application No. PCT/US2014/015274
US Application No. 15/924,012

Publications:
Collins PL, Melero JA. PMID 21963675
Coleman JR, et al. PMID 18583614

Licensing Contact:
Peter Soukas, J.D.
Email: peter.soukas@nih.gov
Phone: 301-496-2644

OTT Reference No: E-080-2013-0
Updated: Jun 6, 2013